Phase 3 PTSD Trial, Recruiting NCT07703722 Sponsor: Khyber Medical University Peshawar Condition: PTSD
Back to Ptsd

Phase 3 PTSD Trial, Recruiting

NCT07703722
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between the ages of 18 and 60 years old
  • People who have been diagnosed with Major Depressive Disorder (MDD) based on standard medical criteria (DSM-5)
  • People whose depression is connected to trauma and who have significant trauma-related symptoms
  • People whose depression severity scores above a certain level on a standard rating scale called the HAM-D (confirm with trial site)
  • People whose trauma-related symptom scores are above a certain level on a checklist called the PCL-5 (confirm with trial site)
  • People whose anxiety scores are above a certain level on a standard scale called the GAD-7 (confirm with trial site)
  • People who have been taking a single SSRI antidepressant consistently and without changes for at least 6 weeks before joining the trial
  • People who are able and willing to sign a consent form agreeing to take part
  • People who are willing to attend all study visits and follow all study procedures
  • Women who could become pregnant must agree to use effective birth control for the entire duration of the study

Who may not be able to join:

  • People with serious heart or cardiovascular conditions
  • People with significant liver or kidney problems
  • People with significant neurological conditions affecting the brain or nervous system
  • People who currently have or have previously had a psychotic disorder or bipolar disorder
  • People who currently have a problem with alcohol or drug use, including past or current use of ketamine or psychedelic drugs
  • People who are taking more than one antidepressant medication
  • People who are pregnant, planning to become pregnant, or currently breastfeeding
  • People who have a known allergy or medical reason they cannot take psilocybin
  • People who have taken part in another clinical trial within the past 30 days
  • People who are not able or willing to sign a consent form
  • People who have any other medical or mental health condition that the trial doctor believes could make participation unsafe or affect the study results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Dr Omer Malik, PhD, Khyber Medical University Peshawar, Pakistan

Phone: +92 3338000744

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Khyber Medical University Peshawar
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
22 October 2027

Where this trial is recruiting

🇵🇰 Pakistan

Primary endpoints

Depression Severity; Trauma-Related Symptoms; Anxiety Severity; Gut-Brain Axis and Neuroinflammatory Biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov